Top Buy Now Summary References
Home
>
Section
>
Chapter

Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose

Le Moine, C.; Soyfoo, M.S.; Mekkaoui, L.; Dahma, H.; Tant, L.

Clinical and Experimental Rheumatology 41(1): 82-87

2023

ISSN/ISBN: 0392-856X
PMID: 35699073
Accession: 080025130

Full-Text Article emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Summary
We aimed to assess SARS-CoV-2 spike-specific antibody kinetics postvaccination and the benefit of a mRNA vaccine booster dose in rheumatoid arthritis (RA) patients treated with immunosuppressive drugs. Consecutive RA patients on immunosuppressive therapies, with no known history of SARS-CoV-2 infection or high-risk contact, vaccinated with 2 doses SARS-CoV-2 mRNA, BNT162b2 or mRNA-1273, or viral vectored ChAdOx1 nCoV-19 vaccine were recruited during their routine rheumatology consultation. Anti-SARS-CoV-2 IgG spike-specific antibodies were quantified at 1, 3 and 6 months respectively following the second vaccine dose. The incidence of SARS-CoV-2 infection post-vaccination during this 6-month longitudinal study was also assessed. Of the 104 RA patients included, 79 patients completed the 6-month trial follow-up. A significant decrease in anti-SARS-CoV-2 spike-specific IgG titres was observed between 1-month and 3-month postvaccination (p<0.01). Among the 46 patients (46/79) receiving a booster dose, all developed detectable anti-SARS-CoV-2 spike-specific IgG antibodies at the 6-month follow-up with significantly higher titres compared to 1-month (p<0.001) and 3-month (p<0.0001) post-vaccination. Conversely, the antibody titres among the 33 patients (33/79) not receiving a booster dose decreased significantly at the 6-month follow-up compared to 1-month (p<0.0001) and 3-month (p<0.01) post-vaccination. The incidence of COVID-19 disease postvaccination was 8.9% without severe forms. To our knowledge, this is the first study to report on anti-SARS-CoV-2 spike-specific antibody kinetics postvaccination and the effect of a booster dose in a cohort of RA patients. The latter is essential given the waning humoral immunity observed in vaccinated RA patients and the increased incidence of COVID-19 diseases postvaccination in this 6-month longitudinal study.

References

León, U.A.-P.d.; Pérez, A.G.C.; Avila-Vales, E. 2023: Modeling the SARS-CoV-2 Omicron variant dynamics in the United States with booster dose vaccination and waning immunity Mathematical Biosciences and Engineering: Mbe 20(6): 10909-10953
Da Penha Gomes Gouvea, M.; Lira Machado, K.L.L.; de Oliveira, Y.G.P.; Moulaz, I.R.; Henriques, A.G.ça.; Gouveia, T.á M.; Thompson, B.P.; Lança, K.E.M.; de Souza Ramos, S.; Lacerda, G.C.C.; Lenzi, J.ão.P.G.ça.; de Castro Pimentel, F.; Miossi, J.ão.P.M.; Rassele, M.L.; Camacho, L.A.ôn.B.; Villela, D.A.M.; de Lima, S.M.B.; de Souza Azevedo, A.; Horbach, I.S.; de Araújo, M.F.; Tort, L.F.L.; de Oliveira, A.C.A.; Siqueira, M.M.ça.; Garcia, C.C.; da Costa-Rocha, I.A.; Campi-Azevedo, A.C.; Peruhype-Magalhães, V.; da Silva, V.éz.G.ça.; Miyamoto, S.T.; Dos Santos Fantoni, R.N.; Pinto-Neto, L.F.; Magda Domingues, C.; de Medeiros Junior, N.és.F.; Burian, A.P.; Teixeira-Carvalho, A.éa.; Mota, L.M.H.; Mill, J.é G.; Martins-Filho, O.A.; Val 2023: Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose Vaccine 41(44): 6514-6528
Altmann, D.M.; Boyton, R.J. 2021: Waning immunity to SARS-CoV-2: implications for vaccine booster strategies LANCET. Respiratory Medicine 9(12): 1356-1358
Yang, L.M.; Costales, C.; Ramanathan, M.; Bulterys, P.L.; Murugesan, K.; Schroers-Martin, J.; Alizadeh, A.A.; Boyd, S.D.; Brown, J.M.; Nadeau, K.C.; Nadimpalli, S.S.; Wang, A.X.; Busque, S.; Pinsky, B.A.; Banaei, N. 2022: Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 153: 105217
Jung, J.; Kim, J.Y.; Kwon, J.-S.; Yun, S.-C.; Kim, S.-H. 2022: Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination with BNT162b2 Immune Network 22(4): E31
Augello, M.; Bono, V.; Rovito, R.; Santoro, A.; Tincati, C.; Marchetti, G. 2024: Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV Aids 38(14): 1987-1990
Balkan, İl.İn.; Dinc, H.O.; Can, G.; Karaali, R.ıd.; Ozbey, D.; Caglar, B.; Beytur, A.şe.N.; Keskin, E.; Budak, B.; Aydogan, O.; Mete, B.ül.; Ergin, S.; Kocazeybek, B.; Saltoglu, N. 2023: Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required Irish Journal of Medical Science 192(1): 19-25
Kvist-Hansen, A.; Hansen, C.B.; Hamm, S.R.; Prez-Als, L.; Zachariae, C.; Nielsen, S.D.; Garred, P.; Skov, L. 2024: Humoral immunity after a booster dose of COVID-19 vaccine in patients with psoriasis treated with methotrexate and biologics: a cohort study Clinical and experimental dermatology 50(1): 178-181
Goggins, E.; Sharma, B.; Ma, J.Z.; Gautam, J.; Bowman, B. 2023: SARS-CoV-2 booster effect and waning immunity in hemodialysis patients: a cohort study Health Science Reports 6(1): E1040
Hasmann, S.; Paal, M.; Füeßl, L.; Fischereder, M.; Schönermarck, U. 2021: Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients: (Response to: Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.) Lancet Regional Health. Europe 10: 100237
Bernea, L.; Ailioaie, O.R.; Benhamouda, N.; Tartour, E.; Germain, D.P. 2021: Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens Vaccines 9(12)
Zember, S.; Bodulić, K.; Balent, N.ša.C.ć; Mikulić, R.; Markotić, A.; Đaković Rode, O. 2022: Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination Vaccines 10(11)
Edmunds, W.J.; Medley, G.F.; Nokes, D.J. 1996: Vaccination against hepatitis B virus in highly endemic areas: waning vaccine-induced immunity and the need for booster doses Transactions of the Royal Society of Tropical Medicine and Hygiene 90(4): 436-440
Vesin, B.; Lopez, J.; Noirat, A.; Authié, P.; Fert, I.; Le Chevalier, F.; Moncoq, F.; Nemirov, K.; Blanc, C.; Planchais, C.; Mouquet, H.; Guinet, F.ço.; Hardy, D.; Vives, F.L.; Gerke, C.; Anna, F.ço.; Bourgine, M.; Majlessi, L.; Charneau, P. 2022: An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa Molecular Therapy: the Journal of the American Society of Gene Therapy 30(9): 2984-2997
Venerito, V.; Stefanizzi, P.; Martinelli, A.; Fornaro, M.; Galeone, M.G.; Tafuri, S.; Iannone, F.; Lopalco, G. 2023: Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors Clinical and Experimental Rheumatology 41(1): 166-169
Swain, N.; Tripathy, A.; Sahoo, B.; Padhan, P.; Raghav, S.K.; Gupta, B. 2025: SARS-CoV-2 vaccine induced humoral and cell-mediated immune responses in Indian cohort of rheumatoid arthritis Indian Journal of Medical Research 162(4): 520-528
Nguyen, L.B.L.; Ghosn, J. 2026: Pro/con: vaccination and waning immunity - presents contrasting perspectives on the durability of vaccine-induced protection and the potential need for booster strategies Current Opinion in HIV and Aids 2026
Espi, M.; Charmetant, X.; Mathieu, C.; Lalande, A.; Decimo, D.; Koppe, L.; Pelletier, C.; Ovize, A.; Barbry, A.; Morelon, E.; Kalbacher, E.; Fouque, D.; Thaunat, O. 2023: Rapid Waning of Immune Memory Against SARS-CoV-2 in Maintenance Hemodialysis Patients After mRNA Vaccination and Impact of a Booster Dose Kidney International Reports 8(4): 907-911
Goggins, E.; Sharma, B.; Ma, J.Z.; Gautam, J.; Bowman, B. 2024: Humoral immunity trends in a hemodialysis cohort following SARS-CoV-2 mRNA booster: a cohort study Health Science Reports 7(2): E1858
Berar-Yanay, N.; Freiman, S.; Shapira, M.ʹa.; Saffoury, A.; Elemy, A.; Hamze, M.; Elhaj, M.; Zaher, M.; Matanis, L.; Armaly, Z.A. 2021: Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients Journal of Clinical Medicine 11(1)